Damora Therapeutics, Inc. (DMRA): Cash & Equivalents
$257.62M
As of 2025-12-31
$540.51M
As of 2026-06-30
+98.8%
3-year compound annual growth
+9.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $257.62M | n/m | 2026-03-19, Balance as of period end |
| 2024-12-31 | $14.18M | -34.0% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $21.46M | -34.5% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $32.79M | -47.6% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $62.56M | -61.8% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $163.58M | n/m | 2022-02-17, Balance as of period end |
| 2019-12-31 | $11.29M | n/a | 2021-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $257.62M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $58.45M | +52.4% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $57.22M | -68.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $28.65M | +11.0% |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $30.63M | -50.3% |
| Savara Inc (SVRA) | 2025-12-31 | $33.18M | +119.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.91M | -2.6% |
Compare DMRA, NATR, PHAT, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗